Reata Pharmaceuticals, Inc. (NASDAQ:RETA) Expected to Post Quarterly Sales of $1.41 Million


Share on StockTwits

Equities research analysts expect that Reata Pharmaceuticals, Inc. (NASDAQ:RETA) will post sales of $1.41 million for the current quarter, according to Zacks Investment Research. Four analysts have provided estimates for Reata Pharmaceuticals’ earnings. The highest sales estimate is $2.00 million and the lowest is $1.10 million. Reata Pharmaceuticals posted sales of $1.35 million in the same quarter last year, which would indicate a positive year over year growth rate of 4.4%. The firm is scheduled to announce its next earnings report on Monday, May 10th.

According to Zacks, analysts expect that Reata Pharmaceuticals will report full-year sales of $8.15 million for the current financial year, with estimates ranging from $4.70 million to $11.25 million. For the next financial year, analysts forecast that the firm will report sales of $181.50 million, with estimates ranging from $60.11 million to $256.23 million. Zacks’ sales averages are a mean average based on a survey of research analysts that cover Reata Pharmaceuticals.

Reata Pharmaceuticals (NASDAQ:RETA) last posted its earnings results on Monday, March 1st. The company reported ($1.90) earnings per share (EPS) for the quarter, topping the consensus estimate of ($2.14) by $0.24. The firm had revenue of $3.19 million for the quarter, compared to the consensus estimate of $1.20 million. Reata Pharmaceuticals had a negative return on equity of 163.42% and a negative net margin of 4,340.72%. The business’s quarterly revenue was up 19.5% on a year-over-year basis. During the same quarter in the prior year, the business posted ($5.91) earnings per share.

Several large investors have recently bought and sold shares of RETA. Duquesne Family Office LLC lifted its position in shares of Reata Pharmaceuticals by 37.9% during the fourth quarter. Duquesne Family Office LLC now owns 749,897 shares of the company’s stock worth $92,702,000 after acquiring an additional 205,996 shares in the last quarter. Price T Rowe Associates Inc. MD lifted its position in shares of Reata Pharmaceuticals by 21.8% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 1,120,922 shares of the company’s stock worth $138,568,000 after acquiring an additional 200,996 shares in the last quarter. Norges Bank purchased a new stake in shares of Reata Pharmaceuticals during the fourth quarter worth $24,820,000. Deerfield Management Company L.P. Series C lifted its position in shares of Reata Pharmaceuticals by 71.1% during the third quarter. Deerfield Management Company L.P. Series C now owns 448,000 shares of the company’s stock worth $43,644,000 after acquiring an additional 186,235 shares in the last quarter. Finally, Baker BROS. Advisors LP lifted its position in shares of Reata Pharmaceuticals by 321.1% during the fourth quarter. Baker BROS. Advisors LP now owns 223,976 shares of the company’s stock worth $27,688,000 after acquiring an additional 170,793 shares in the last quarter. Hedge funds and other institutional investors own 64.30% of the company’s stock.

Shares of NASDAQ:RETA traded up $0.54 during trading on Monday, hitting $97.72. 1,399 shares of the company were exchanged, compared to its average volume of 286,876. The company has a market cap of $3.54 billion, a PE ratio of -8.68 and a beta of 1.57. The stock has a 50 day moving average of $115.94 and a 200 day moving average of $122.29. Reata Pharmaceuticals has a 52-week low of $88.17 and a 52-week high of $186.82.

Reata Pharmaceuticals Company Profile

Reata Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, develops novel therapeutics for patients with serious or life-threatening diseases by targeting molecular pathways that regulate cellular metabolism and inflammation. The company is developing Phase III clinical trial programs, including bardoxolone methyl (bardoxolone) for the treatment of patients with chronic kidney disease (CKD) caused by Alport syndrome, as well as for a form of pulmonary arterial hypertension associated with connective tissue disease; omaveloxolone that is Phase II clinical trial to treat Friedreich's ataxia; and conduct Phase II study for various form of CKD, such as IgA nephropathy, type 1 and type 2 diabetic CKD, hypertensive CKD, focal segmental glomerulosclerosis, and others.

Further Reading: NASDAQ Stock Market Explained

Get a free copy of the Zacks research report on Reata Pharmaceuticals (RETA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Reata Pharmaceuticals (NASDAQ:RETA)

Receive News & Ratings for Reata Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Reata Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.